Endocrinology focuses on hormonal system and metabolic health. Learn about the diagnosis and treatment of diabetes, thyroid disorders, and adrenal conditions.
Send us all your questions or requests, and our expert team will assist you.
The overview and definition of pheochromocytoma begins with recognizing it as a rare, catecholamine‑producing tumor that arises from chromaffin cells of the adrenal medulla. This condition, though uncommon, can have profound effects on cardiovascular health and overall well‑being. International patients seeking specialized endocrine care often turn to Liv Hospital for its JCI‑accredited expertise, comprehensive diagnostic pathways, and personalized treatment plans.
In this page we provide a detailed overview and definition of pheochromocytoma, explain why early detection matters, and outline the full spectrum of clinical management—from initial suspicion to long‑term follow‑up. Whether you are a patient, a family member, or a healthcare professional, the information below will help you understand the disease, its impact, and the state‑of‑the‑art care available at Liv Hospital.
Did you know that up to 30% of patients with untreated pheochromocytoma experience life‑threatening hypertensive crises? This statistic underscores the importance of timely diagnosis and expert management, both of which are integral components of the services offered at our Istanbul facility.
Pheochromocytoma is a neuroendocrine tumor that originates from the chromaffin cells of the adrenal medulla, the inner part of the adrenal gland located atop each kidney. These cells normally produce catecholamines—primarily adrenaline (epinephrine) and noradrenaline (norepinephrine)—which regulate the body’s “fight‑or‑flight” response. When a tumor develops, it secretes excess catecholamines, leading to episodic or sustained hypertension, palpitations, sweating, and a range of systemic effects.
The tumor can also arise from extra‑adrenal chromaffin tissue, known as paragangliomas, which share similar biochemical behavior. While most pheochromocytomas are benign, approximately 10–15% may be malignant, spreading to distant organs such as the lungs, liver, or bone. Genetic factors play a notable role; mutations in genes like RET, VHL, NF1, SDHB, and SDHD are associated with hereditary syndromes that increase tumor risk.
Understanding the overview and definition of pheochromocytoma is essential for clinicians to differentiate it from other causes of secondary hypertension and to initiate appropriate investigations promptly.
The exact cause of pheochromocytoma remains unclear, but several risk factors increase susceptibility:
Identifying these risk factors enables targeted screening for high‑risk individuals, especially those planning international medical travel for specialized endocrine evaluation.
Because pheochromocytoma secretes catecholamines intermittently, patients often experience a classic triad of symptoms, but the presentation can be highly variable. The table below summarizes the most common clinical features and their typical frequency:
Additional manifestations may include anxiety, tremor, and, in rare cases, life‑threatening hypertensive emergencies. Because symptoms can mimic other conditions such as anxiety disorders or essential hypertension, a high index of suspicion is crucial, especially for patients traveling for specialist care.
Accurate diagnosis of pheochromocytoma relies on a combination of biochemical screening and imaging studies. The diagnostic algorithm typically follows these steps:
The comparison table below highlights the strengths of each imaging modality:
Liv Hospital’s multidisciplinary team integrates these diagnostic tools with international patient coordination, ensuring seamless testing regardless of the patient’s country of origin.
Management of pheochromocytoma is tailored to tumor size, location, genetic background, and patient health status. The primary therapeutic goals are complete tumor removal, normalization of catecholamine levels, and prevention of recurrence.
The table below contrasts surgical versus medical approaches:
Liv Hospital’s surgeons are experienced in both minimally invasive and open techniques, supported by anesthesiologists skilled in peri‑operative catecholamine management, ensuring optimal outcomes for international patients.
After definitive treatment, diligent follow‑up is vital to detect recurrence early and to manage any residual hormonal effects. Recommended surveillance includes:
Overall prognosis is favorable for patients with benign, completely resected tumors, with 5‑year survival rates exceeding 95%. Malignant disease carries a more guarded outlook, but advances in targeted radionuclide therapy and personalized medicine have improved median survival to several years.
Liv Hospital provides a dedicated endocrine follow‑up clinic, offering tele‑medicine consultations for patients returning to their home countries, ensuring continuity of care across borders.
Liv Hospital combines JCI accreditation, a multilingual care team, and cutting‑edge technology to deliver world‑class endocrine services for international patients. Our comprehensive package includes appointment coordination, airport transfers, interpreter assistance, and comfortable accommodation options, allowing patients to focus solely on their health journey.
With a proven track record in managing complex tumors such as pheochromocytoma, our specialists employ evidence‑based protocols and personalized treatment plans, ensuring safety, effectiveness, and a seamless experience from diagnosis to recovery.
Ready to take the next step toward expert care for pheochromocytoma? Contact Liv Hospital today to schedule a personalized consultation and benefit from our full suite of international patient services.
Our dedicated team will guide you through every stage, from initial testing to post‑treatment follow‑up, ensuring peace of mind wherever you are.
Liv Hospital Ulus
Assoc. Prof. MD. Seda Turgut
Endocrinology and Metabolism
Liv Hospital Ulus
Prof. MD. Demet Yetkin
Endocrinology and Metabolism
Liv Hospital Vadistanbul
Prof. MD. Berçem Ayçiçek
Endocrinology and Metabolism
Liv Hospital Vadistanbul
Prof. MD. Gönül Çatlı
Pediatric Endocrinology
Liv Hospital Vadistanbul
Prof. MD. Kubilay Ükinç
Endocrinology and Metabolism
Liv Hospital Bahçeşehir
Assoc. Prof. MD. Sevil Arı Yuca
Pediatric Endocrinology and Metabolic Diseases
Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ufuk Özuğuz
Endocrinology and Metabolism
Liv Hospital Bahçeşehir
Spec. MD. Hüseyin Çelik
Endocrinology and Metabolism
Liv Hospital Topkapı
Prof. MD. Mehmet Aşık
Endocrinology and Metabolism
Liv Hospital Topkapı
Prof. MD. Nujen Çolak Bozkurt
Endocrinology and Metabolism
Liv Hospital Ankara
Prof. MD. Banu Aktaş Yılmaz
Endocrinology and Metabolism
Liv Hospital Ankara
Prof. MD. Peyami Cinaz
Pediatric Endocrinology
Liv Hospital Ankara
Prof. MD. Serdar Güler
Endocrinology and Metabolism
Liv Hospital Ankara
Spec. MD. Elif Sevil Alagüney
Endocrinology and Metabolism
Liv Hospital Gaziantep
Prof. MD. Zeynel Beyhan
Endocrinology and Metabolic Diseases
Liv Hospital Gaziantep
Spec. MD. Tahsin Özenmiş
Endocrinology and Metabolism
Liv Hospital Samsun
Assoc. Prof. MD. Gülçin Cengiz Ecemiş
Endocrinology and Metabolism
Liv Hospital Samsun
Spec. MD. Esra Tutal
Endocrinology and Metabolic Diseases
Liv Bona Dea Hospital Bakü
MD. FİDAN QULU
Endocrinology and Metabolism
Spec. MD. Zümrüt Kocabey Sütçü
Pediatric Endocrinology
Liv Hospital Ulus + Liv Hospital Vadistanbul + Liv Hospital Topkapı
Prof. MD. Cengiz Kara
Pediatric Endocrinology
Send us all your questions or requests, and our expert team will assist you.
Pheochromocytoma originates in the chromaffin cells of the adrenal medulla, the inner part of each adrenal gland. These cells normally produce catecholamines—adrenaline and noradrenaline—that regulate the fight‑or‑flight response. When a tumor develops, it secretes excess catecholamines, causing episodic hypertension, palpitations, sweating, and other systemic effects. In some cases the tumor can arise from extra‑adrenal chromaffin tissue, known as paraganglioma, which behaves similarly.
Approximately 40% of pheochromocytoma cases have a hereditary basis. The most common pathogenic variants involve the RET gene (associated with MEN 2), the VHL gene (von Hippel‑Lindau disease), NF1 (neurofibromatosis type 1), and the succinate dehydrogenase subunit genes SDHB and SDHD. These mutations increase the risk of developing adrenal or extra‑adrenal tumors and often dictate a more aggressive surveillance strategy for patients and their families.
Patients with pheochromocytoma often present with a classic triad: sudden spikes in blood pressure (paroxysmal hypertension), throbbing headaches, and excessive sweating (diaphoresis). Additional symptoms can include palpitations, flushing, weight loss, hyperglycemia, anxiety, tremor, and in severe cases hypertensive emergencies. Because these manifestations overlap with common conditions like anxiety disorders, a high index of suspicion is required, especially in patients with risk factors or a family history.
The diagnostic work‑up starts with biochemical confirmation—measurement of plasma free metanephrines or 24‑hour urinary fractionated metanephrines, which have high sensitivity. If results are positive, imaging is performed to localize the tumor. First‑line imaging includes contrast‑enhanced CT or MRI of the abdomen. Functional studies such as ¹²³I‑MIBG scintigraphy or ⁶⁸Ga‑DOTATATE PET are reserved for extra‑adrenal disease, metastatic spread, or when CT/MRI are inconclusive. Genetic testing is recommended for patients with a family history, early onset, or bilateral lesions.
The definitive treatment for pheochromocytoma is surgical resection. Laparoscopic adrenalectomy is preferred for unilateral, non‑invasive tumors, while open surgery may be needed for large (>6 cm) or invasive lesions. Pre‑operative management includes alpha‑adrenergic blockade (e.g., phenoxybenzamine) followed by beta‑blockade to control blood pressure and prevent intra‑operative crises. For patients who cannot undergo surgery, medical therapy focuses on symptom control with alpha‑blockers and beta‑blockers. Malignant or metastatic disease may be treated with ¹³¹I‑MIBG radiotherapy, peptide receptor radionuclide therapy (PRRT), or targeted tyrosine‑kinase inhibitors.
After curative surgery, patients should undergo plasma or urinary metanephrine testing at 6 months and then annually for at least 10 years. Imaging (CT or MRI) is recommended every 2–3 years, especially for those with hereditary mutations that carry a higher recurrence risk. Ongoing blood pressure monitoring, cardiovascular risk assessment, and psychological support are also important, as residual catecholamine effects can persist and the diagnosis often causes anxiety. Liv Hospital offers tele‑medicine follow‑up for international patients to ensure continuity of care.
BlogEndocrinologyApr 13, 2026Discover the definition, symptoms, and hormone secretion of pheochromocytoma (pheo), a rare tumor that can ...
BlogEndocrinologyApr 13, 2026Discover the latest treatments for pheochromocytoma, including alpha and beta blockers. Learn what ADH stan...
BlogEndocrinologyApr 13, 2026Explore the 7 key symptoms of pituitary hypothalamic pheochromocytoma, a rare neuroendocrine tumor. Learn a...
BlogEndocrinologyApr 13, 2026Learn the key facts about what happens when you're on your period. Our guide provides insights into the dia...
BlogEndocrinologyApr 13, 2026Learn the role of alpha blockers in treating pheochromocytoma, a rare adrenal gland tumor. Our comprehensiv...
BlogEndocrinologyApr 13, 2026Discover the common symptoms of adrenal gland masses in women, including fatigue, weight changes, and hormo...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 28 17